Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1958 Jan 4;1(5061):1–7. doi: 10.1136/bmj.1.5061.1

The Chemotherapy of Malignant Disease*

Ronald Bodley Scott
PMCID: PMC2026603  PMID: 13489293

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARMISTEAD G. C., Jr, BURCHENAL J. H. Preliminary studies on the clinical toxicity of 5-amino-7-hydroxy-1-v-triazolo[d]-pyrimidine. Cancer. 1949 Nov;2(6):1087–illust. doi: 10.1002/1097-0142(194911)2:6<1087::aid-cncr2820020614>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. AXELROD A. R., BERMAN L., MURPHY R. V. Clinical and hematologic effects of triethylene melamine. Am J Med. 1953 Nov;15(5):684–694. doi: 10.1016/0002-9343(53)90157-0. [DOI] [PubMed] [Google Scholar]
  3. Adair F. E., Bagg H. J. EXPERIMENTAL AND CLINICAL STUDIES ON THE TREATMENT OF CANCER BY DICHLORETHYLSULPHIDE (MUSTARD GAS. Ann Surg. 1931 Jan;93(1):190–199. doi: 10.1097/00000658-193101000-00026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BATEMAN J. C., CARLTON H. N. Palliation of mammary carcinoma with phosphoramide drugs. J Am Med Assoc. 1956 Oct 20;162(8):701–706. doi: 10.1001/jama.1956.02970250001001. [DOI] [PubMed] [Google Scholar]
  5. BAYRD E. D., STICKNEY J. M., HALL B. E., WATKINS C. H. Clinical observations on the use of triethylenemelamine. Cancer. 1952 Mar;5(2):336–343. doi: 10.1002/1097-0142(195203)5:2<336::aid-cncr2820050222>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. BENDICH A., RUSSELL P. J., Jr, BROWN G. B. On the heterogeneity of the desoxyribonucleic acids. J Biol Chem. 1953 Jul;203(1):305–318. [PubMed] [Google Scholar]
  7. BLACKBURN E. K., KING G. M., SWAN H. T. Myleran in treatment of chronic myeloid leukaemia. Br Med J. 1956 Apr 14;1(4971):835–837. doi: 10.1136/bmj.1.4971.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. BOURONCLE B. A., DOAN C. A., WISEMAN B. K., FRAJOLA W. J. Evaluation of CB 1348 in Hodgkin's disease and allied disorders. AMA Arch Intern Med. 1956 Jun;97(6):703–714. doi: 10.1001/archinte.1956.00250240055005. [DOI] [PubMed] [Google Scholar]
  9. BOUSSER J., CHRISTOL D. Essais de chimiothérapie de la leucémie myéloïde par 3 corps nouveaux: démécolcine, thiocolchicine, myleran. Presse Med. 1955 Sep 21;63(61):1229–1231. [PubMed] [Google Scholar]
  10. BROSS I. D. Statistical analysis of clinical results from 6-mercaptopurine. Ann N Y Acad Sci. 1954 Dec 6;60(2):369–373. doi: 10.1111/j.1749-6632.1954.tb40025.x. [DOI] [PubMed] [Google Scholar]
  11. BROWN G. L., WATSON M. Heterogeneity of deoxyribonucleic acids. Nature. 1953 Aug 15;172(4372):339–342. doi: 10.1038/172339b0. [DOI] [PubMed] [Google Scholar]
  12. BURCHENAL J. H., KARNOFSKY D. A., KINGSLEY-PILLERS E. M., SOUTHAM C. M., MYERS W. P. L., ESCHER G. C., CRAVER L. F., DARGEON H. W., RHOADS C. P. The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia. Cancer. 1951 May;4(3):549–569. doi: 10.1002/1097-0142(195105)4:3<549::aid-cncr2820040308>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  13. BURCHENAL J. H., MURPHY M. L., ELLISON R. R., SYKES M. P., TAN T. C., LEONE L. A., KARNOFSKY D. A., CRAVER L. F., DARGEON H. W., RHOADS C. P. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953 Nov;8(11):965–999. [PubMed] [Google Scholar]
  14. BURCHENAL J. H. Present status of ACTH, cortisone, and the antimetabolites in the treatment of leukemia and related diseases. Acta Haematol. 1952 Apr;7(4):193–205. doi: 10.1159/000204053. [DOI] [PubMed] [Google Scholar]
  15. CARRINGTON H. C., CROWTHER A. F., DAVEY D. G., LEVI A. A., ROSE F. L. A metabolite of paludrine with high antimalarial activity. Nature. 1951 Dec 22;168(4288):1080–1080. doi: 10.1038/1681080a0. [DOI] [PubMed] [Google Scholar]
  16. CHARGAFF E., CRAMPTON C. F., LIPSHITZ R. Separation of calf thymus deoxyribonucleic acid into fractions of different composition. Nature. 1953 Aug 15;172(4372):289–292. doi: 10.1038/172289a0. [DOI] [PubMed] [Google Scholar]
  17. CONSOLI G., NAPOLI V. M. I dimetansulfonilossidi e la terapia della mielosi leucemica cronica; rassegna della letteratura e contributo casistico. Riforma Med. 1955 Aug 20;69(34):929–937. [PubMed] [Google Scholar]
  18. COOPER T., WATKINS C. H. Ethyl carbamate (urethane) in the treatment of chronic myelocytic leukemia; results of a three-year study. Med Clin North Am. 1950 Jul;34(4):1205–1215. [PubMed] [Google Scholar]
  19. CROIZAT P., LACOSTE Essai de l'actinomycine C dans le traitement des adénopathies malignes. Presse Med. 1955 Dec 3;63(81):1681–1681. [PubMed] [Google Scholar]
  20. ELLISON R. R., KARNOFSKY D. A., STERNBERG S. S., MURPHY M. L., BURCHENAL J. H. Clinical trials of O-diazoacetyl-L-serine (azaserine) in neoplastic disease. Cancer. 1954 Jul;7(4):801–814. doi: 10.1002/1097-0142(195407)7:4<801::aid-cncr2820070419>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  21. Farber S., Cutler E. C., Hawkins J. W., Harrison J. H., Peirce E. C., 2nd, Lenz G. G. The Action of Pteroylglutamic Conjugates on Man. Science. 1947 Dec 19;106(2764):619–621. doi: 10.1126/science.106.2764.619. [DOI] [PubMed] [Google Scholar]
  22. GALTON D. A. G. Aromatic nitrogen mustards in the reticuloses with special reference to R48 [di(2-chloroethyl)-beta-naphthylamine]. Br J Radiol. 1951 Sep;24(285):511–513. doi: 10.1259/0007-1285-24-285-511. [DOI] [PubMed] [Google Scholar]
  23. GALTON D. A., ISRAELS L. G., NABARRO J. D., TILL M. Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma. Br Med J. 1955 Nov 12;2(4949):1172–1176. doi: 10.1136/bmj.2.4949.1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. GELLHORN A., HYMAN G. A., ULTMANN J. E. Chlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomas. J Am Med Assoc. 1956 Sep 15;162(3):178–183. doi: 10.1001/jama.1956.02970200026006. [DOI] [PubMed] [Google Scholar]
  25. GILBERT R., THOMMEN E. A propos des indications de l'actinomycine C dans les tumeurs du système réticulaire. Presse Med. 1955 Dec 3;63(81):1685–1685. [PubMed] [Google Scholar]
  26. Gilman A., Philips F. S. The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides. Science. 1946 Apr 5;103(2675):409–436. doi: 10.1126/science.103.2675.409. [DOI] [PubMed] [Google Scholar]
  27. HADDOW A., TIMMIS G. M. Bifunctional sulphonic acid esters with radiomimetic activity. Acta Unio Int Contra Cancrum. 1951;7(3):469–471. [PubMed] [Google Scholar]
  28. HAMBLY C. K., ROBERTSON T. I. Triethylene melamine (TEM) in the treatment of malignant lymphoid disease. Med J Aust. 1955 Jun 18;42(1 25):900–911. doi: 10.5694/j.1326-5377.1955.tb38360.x. [DOI] [PubMed] [Google Scholar]
  29. HANSEN P. B., BICHEL J. Triethylene melamine therapy in Hodgkin's and other malignant diseases. Acta radiol. 1951 Dec;36(6):469–476. doi: 10.3109/00016925109176999. [DOI] [PubMed] [Google Scholar]
  30. HANSEN P. B. Clinical experience with CB 1348 (NN-di(2-chloroethyl, -P-aminophenylbutyric acid) in the treatment of chronic lymphatic leukaemia. Acta radiol. 1957 Mar;47(3):210–216. doi: 10.3109/00016925709170889. [DOI] [PubMed] [Google Scholar]
  31. HAUT A., ALTMAN S. J., CARTWRIGHT G. E., WINTROBE M. M. The use of myleran in the treatment of chronic myelocytic leukemia. AMA Arch Intern Med. 1955 Oct;96(4):451–462. doi: 10.1001/archinte.1955.00250150025002. [DOI] [PubMed] [Google Scholar]
  32. HEINLE R. W. Treatment of acute leukemia of childhood. Ohio State Med J. 1950 Feb;46(2):133–135. [PubMed] [Google Scholar]
  33. HENDRY J. A., HOMER R. F., ROSE F. L., WALPOLE A. L. Cytotoxic agents: III, derivatives of ethyleneimine. Br J Pharmacol Chemother. 1951 Sep;6(3):357–410. doi: 10.1111/j.1476-5381.1951.tb00650.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. HUGUENIN R., TRUHAUT R., SARACINO R. Premiers resultats de l'utilisation en chimiothérapie anticancéreuse d'un dérivé de la colchicine: la N-désacétyl-thiocolchicine. Bull Assoc Fr Etud Cancer. 1955;42(3):308–325. [PubMed] [Google Scholar]
  35. Hitchings G. H., Falco E. A., Sherwood M. B. THE EFFECTS OF PYRIMIDINES ON THE GROWTH OF LACTOBACILLUS CASEI. Science. 1945 Sep 7;102(2645):251–252. doi: 10.1126/science.102.2645.251. [DOI] [PubMed] [Google Scholar]
  36. INNES J., RIDER W. D. Multiple myelomatosis treated with a combination of urethane and an oral nitrogen mustard. Blood. 1955 Mar;10(3):252–258. [PubMed] [Google Scholar]
  37. KARNOFSKY D. A., BURCHENAL J. H., ARMISTEAD G. C., Jr, SOUTHAM C. M., BERNSTEIN J. L., CRAVER L. F., RHOADS C. P. Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use. AMA Arch Intern Med. 1951 Apr;87(4):477–516. doi: 10.1001/archinte.1951.03810040002001. [DOI] [PubMed] [Google Scholar]
  38. KRAVITZ S. C., DIAMOND H. D., CRAVER L. F. The clinical use of triethylene melamine. Blood. 1952 Jul;7(7):729–742. [PubMed] [Google Scholar]
  39. LARIONOV L. F., SHKODINSKAJA E. N., TROOSHEIKINA V. I., KHOKHLOV A. S., VASINA O. S., NOVIKOVA M. A. Studies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine). Lancet. 1955 Jul 23;269(6882):169–171. doi: 10.1016/s0140-6736(55)92736-7. [DOI] [PubMed] [Google Scholar]
  40. LOUIS J., LIMARZI L. R., BEST W. R. Treatment of chronic granulocytic leukemia with myleran. AMA Arch Intern Med. 1956 Mar;97(3):299–308. doi: 10.1001/archinte.1956.00250210045003. [DOI] [PubMed] [Google Scholar]
  41. MATTHEWS W. B. A trial of beta-naphthyldi-2-chloroethylamine in leukemia, Hodgkin's disease, and allied diseases. Lancet. 1950 May 13;1(6611):896–899. doi: 10.1016/s0140-6736(50)90732-x. [DOI] [PubMed] [Google Scholar]
  42. MOESCHLIN S., MEYER H., LICHTMAN A. Ein neues Colchicum-Nebenalkaloid (Demecolcin Ciba) als Cytostaticum myeloischer Leukämien. Schweiz Med Wochenschr. 1953 Oct 10;83(41):990–994. [PubMed] [Google Scholar]
  43. MURPHY M. L., ELLISON R. R., KARNOFSKY D. A., BURCHENAL J. H. Clinical effects of the dichloro and monochlorophenyl analogues of diamino pyrimidine: antagonists of folic acid. J Clin Invest. 1954 Oct;33(10):1388–1396. doi: 10.1172/JCI103016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. OLESON J. J., BENNETT P. L., HALLIDAY S. L., WILLIAMS J. H. The effect of the hydrolysis products of puromycin on mouse mammary tumors. Acta Unio Int Contra Cancrum. 1955;11(2):161–166. [PubMed] [Google Scholar]
  45. OLMER J. Nouvelles remarques sur le traitement des hémopathies malignes par l'actinomycine C. Presse Med. 1955 Dec 3;63(81):1683–1683. [PubMed] [Google Scholar]
  46. PHILIPS F. S. Recent contributions to the pharmacology of bis(2-haloethyl) amines and sulfides. J Pharmacol Exp Ther. 1950 Aug;99(42):281–323. [PubMed] [Google Scholar]
  47. PHILIPS F. S., THIERSCH J. B. The nitrogen mustard-like actions of 2,4,6-tris (ethylenimino)-s-triazine and other bis(ethylenimines). J Pharmacol Exp Ther. 1950 Dec;100(41):398–407. [PubMed] [Google Scholar]
  48. PRIBILLA W., STOLLBERG G. Die Behandlung myeloischer Leikämien mit Myleran und Demecolcin. Dtsch Med Wochenschr. 1955 Jul 8;80(27-28):1027–1029. doi: 10.1055/s-0028-1116113. [DOI] [PubMed] [Google Scholar]
  49. RAVINA A., PESTEL M. Nouvelles études cliniques sur l'action de l'actinomycine C. Presse Med. 1955 Dec 3;63(81):1686–1687. [PubMed] [Google Scholar]
  50. REESE A. B., HYMAN G. A., MERRIAM G. R., Jr, FORREST A. W., KLIGERMAN M. M. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954 Apr;53(4):505–513. doi: 10.1001/archopht.1955.00930010507007. [DOI] [PubMed] [Google Scholar]
  51. RHOADS C. P. Relationship of nucleic acid anabolism to the treatment of cancer. Med Clin North Am. 1956 May;40(3):923–933. doi: 10.1016/s0025-7125(16)34575-8. [DOI] [PubMed] [Google Scholar]
  52. RUNDLES R. W., BARTON W. B. Triethylene melamine in the treatment of neoplastic disease. Blood. 1952 May;7(5):483–507. [PubMed] [Google Scholar]
  53. SCHILLING R. F., MEYER O. O. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (myleran). N Engl J Med. 1956 May 24;254(21):986–989. doi: 10.1056/NEJM195605242542104. [DOI] [PubMed] [Google Scholar]
  54. SELIGMAN A. M., RUTENBERG A. M., PERSKY L., FRIEDMAN O. M. Effect of 2-chloro-2'-hydroxydiethyl sulfide (hemisulfur mustard) on carcinomatosis with ascites. Cancer. 1952 Mar;5(2):354–363. doi: 10.1002/1097-0142(195203)5:2<354::aid-cncr2820050225>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  55. SHAY H., ZARAFONETIS C., SMITH N., WOLDOW I., SUN D. C. Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia. AMA Arch Intern Med. 1953 Nov;92(5):628–645. doi: 10.1001/archinte.1953.00240230028004. [DOI] [PubMed] [Google Scholar]
  56. SOARES A. D., VALENTE M. P. Terapeutica das leucemias com a desacetilmetilcolchicina. Gaz Med Port. 1955 Mar-Apr;8(2):111–117. [PubMed] [Google Scholar]
  57. STOLL B. A. Advanced cancer treated with nitromin. Med J Aust. 1956 Dec 15;43(24):882–887. doi: 10.5694/j.1326-5377.1956.tb57372.x. [DOI] [PubMed] [Google Scholar]
  58. SYKES M. P., PHILLIPS F. S., KARNOFSKY D. A. Comparative therapeutic activity of the nitrogen mustards and allied compounds. Med Clin North Am. 1956 May;40(3):837–856. doi: 10.1016/s0025-7125(16)34569-2. [DOI] [PubMed] [Google Scholar]
  59. TAN C. T., BURCHENAL J. H. Clinical studies with amicetin. Antibiotic Med Clin Ther (New York) 1956 Jul;3(2):126–131. [PubMed] [Google Scholar]
  60. VIDEBAEK A., KAAE S. Beta-Naphthyl-di-chloroethylamine in the treatment of malignant diseases, particularly Hodgkin's disease. Acta Med Scand. 1954;149(5):361–368. doi: 10.1111/j.0954-6820.1954.tb11446.x. [DOI] [PubMed] [Google Scholar]
  61. WHITE L. P., SHIMKIN M. B. Effects of DL-ethionine in six patients with neoplastic disease. Cancer. 1954 Sep;7(5):867–872. doi: 10.1002/1097-0142(195409)7:5<867::aid-cncr2820070507>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  62. WOLF H. J., GERLICH N. Die klinische Anwendung von Athylenimino-Chinonen bei Tumorkranken. Dtsch Med Wochenschr. 1956 May 25;81(21):806–811. doi: 10.1055/s-0028-1115793. [DOI] [PubMed] [Google Scholar]
  63. WRIGHT L. T., WRIGHT J. C., PRIGOT A., WEINTRAUB S. Remissions caused by tri-ethylene melamine in certain neoplastic diseases. A preliminary report. J Natl Med Assoc. 1950 Nov;42(6):343–351. [PMC free article] [PubMed] [Google Scholar]
  64. Waksman S. A., Woodruff H. B. The Soil as a Source of Microorganisms Antagonistic to Disease-Producing Bacteria. J Bacteriol. 1940 Oct;40(4):581–600. doi: 10.1128/jb.40.4.581-600.1940. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES